Embera NeuroTherapeutics
Manufacturing · Louisiana, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2031 Kings Hwy Ste 230, Shreveport, Loui...Phone Number
(318) 213-0198Website
www.emberaneuro.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Embera NeuroTherapeutics
Embera NeuroTherapeutics is a specialty pharmaceutical company focused on developing innovative treatments for addiction, specifically targeting cocaine and nicotine use disorders. Their lead product, EMB-001, aims to reduce cravings and loss of control by moderating the stress response system, potentially offering a more effective solution than existing treatments. The company is currently advancing EMB-001 into Phase 2 clinical studies, supported by recent financing and grant awards. Embera's mission is to contribute significantly to long-term abstinence and recovery for individuals struggling with various addictions.Explore more
Embera NeuroTherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Embera NeuroTherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Embera NeuroTherapeutics has new funding data
Click to see if Embera NeuroTherapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Embera NeuroTherapeutics recently announced quarterly report
Embera NeuroTherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Embera NeuroTherapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Embera NeuroTherapeutics
Website visits: Recent activity has been detected on your website
Check out if Embera NeuroTherapeutics is spiking on competitors!
Check if Embera NeuroTherapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Embera NeuroTherapeutics
Find 3 more new buyers
Compare Similar Companies to Embera NeuroTherapeutics
Compare insights from companies similar to Embera NeuroTherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Embera NeuroTherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Embera NeuroTherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Embera NeuroTherapeutics.
Embera NeuroTherapeutics financials insights
Gather financial insights about Embera NeuroTherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$4.5M
2015
Series A
$2M
2019
Series B
$4.4M
Embera NeuroTherapeutics Tech Stack
A closer look at the technologies used by Embera NeuroTherapeutics
Embera NeuroTherapeutics News & Media
Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2 Study of EMB-001 in Cocaine Use Disorder
BOSTON & SHREVEPORT, La.--(BUSINESS WIRE)--Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2 Study of EMB-001 in Cocaine Use Disorder.Embera NeuroTherapeutics Completes Series B Financing and Receives Grants to Advance EMB ...
Embera NeuroTherapeutics Completes Series B Financing and Receives Grants to Advance EMB-001 into Phase 2 Clinical Studies in Cocaine Use Disorder and Smoking Cessation - read this article along with other careers information, tips and advice on BioSpaceEmbera NeuroTherapeutics Completes Series B Financing and Receives Grants to Advance EMB-001 into Phase 2 Clinical Studies in Cocaine Use Disorder and Smoking Cessation
BOSTON & SHREVEPORT, La.--(BUSINESS WIRE)--Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced completion of its Series B financing and the receipt of two grant awards which will fund Phase 2 clinical studies for EMB-001 in cocaine use disorder and smoking cessation. EMB-001 is designed to help patients struggling with addiction to maintain abstinence and improve their quality of life by sEmbera NeuroTherapeutics Completes Series B Financing and Receives Grants to Advance EMB ...
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today anno
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Embera NeuroTherapeutics
Sign Up For FreeTo access detailed company insights
Embera NeuroTherapeutics is a specialty pharmaceutical company focused on developing innovative treatments for addiction, specifically targeting cocaine and nicotine use disorders. Their lead product, EMB-001, aims to reduce cravings and loss of control by moderating the stress response system, potentially offering a more effective solution than ex... Read More
